Top Abstract Purchase Related
Home
>
Node
>
Subnode

Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments

Russo, G.; Paganotti, G.M.; Soeria-Atmadja, S.; Haverkamp, M.; Ramogola-Masire, D.; Vullo, V.; Gustafsson, L.L.

Infection Genetics and Evolution Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 37: 192-207

2016

ISSN/ISBN: 1567-7257
PMID: 26602158
DOI: 10.1016/j.meegid.2015.11.014
Document Number: 640999
The burden of human immunodeficiency virus (HIV) is mainly concentrated to resources-limited countries where the response to available antiretroviral therapy is often limited by the occurrence of toxicity or by the emergence of HIV drug resistance. Efavirenz and nevirapine are the antiretroviral drugs most prescribed in resources-limited countries as part of antiretroviral combination therapy. Their metabolism and conjugation are largely influenced by enzymatic genetic polymorphisms. The genetic variability of their metabolism could be associated to different metabolic phenotypes causing reduced patients' adherence because of toxicity or drug-drug interactions with concomitant therapies. The purpose of this review is to summarize published evidence on pharmacogenetic and pharmacokinetic aspects related to efavirenz and nevirapine, the influence of concomitant anti-tubercular, anti-malarial or contraceptive treatments, and the impact of human genetic variation and drug-drug interaction on the virologic and immunologic response to antiretroviral therapy in resources-limited countries.

Document emailed within 0-6 h
Secure & encrypted payments

Mankhatitham, W.; Luaengniyomkul, A.; Manosuthi, W. 2012: Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy Journal of the Medical Association of Thailand 95(2): 163-169
Engchanil, C.; Kosalaraksa, P.; Lulitanond, V.; Lumbiganon, P.; Chantratita, W. 2006: Multi-drug resistant HIV-1 reverse transcriptase genotype in children treated with dual nucleoside reverse transcriptase inhibitors (NRTIs) Journal of the Medical Association of Thailand 89(10): 1713-1720
Mankhatitham, W.; Lueangniyomkul, A.; Manosuthi, W. 2011: Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen Southeast Asian Journal of Tropical Medicine and Public Health 42(3): 651-658
2000: Non-nucleoside reverse transcriptase inhibitors. First line therapy MMW Fortschritte der Medizin 142(3 Suppl): 34-35
Vitoria, M.; Ford, N.; Doherty, M.; Flexner, C. 2014: Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settings Antiviral Therapy 19(Suppl 3): 31-37
Lawn, S.D.; Wood, R. 2006: Impact of antituberculosis treatment on virological response to highly active antiretroviral therapy: implications for resource-limited settings? Journal of Infectious Diseases 194(10): 1467-8; Author Reply 1468
Aurpibul, L.; Puthanakit, T.; Taecharoenkul, S.; Sirisanthana, T.; Sirisanthana, V. 2009: Reversal of growth failure in HIV-infected Thai children treated with non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy Aids Patient Care and Stds 23(12): 1067-1071
Nachega, J B; Mills, E J 2007: Antiretroviral therapy adherence in resource-limited and resource-rich settings: current status of knowledge and research priorities Therapy 4(6): 775-786
Brzezińska, E.; Glinka, R. 2002: Search for new non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-1 RT) Acta Poloniae Pharmaceutica 59(5): 379-386
Walensky, R.P.; Wolf, L.L.; Wood, R.; Fofana, M.O.; Freedberg, K.A.; Martinson, N.A.; Paltiel, A.D.; Anglaret, X.; Weinstein, M.C.; Losina, E.; Messou, E.èn.; Seyler, C.; Touré, S.; Yazdanpanah, Y.; Kumarasamy, N.; Ganesh, J.; Ganesh, A.K.; Gray, G.; McIntyre, J.; Mohapi, L.; Cotich, K.; Goldie, S.; Horsburgh, C.R.; Kimmel, A.; Lipsitch, M.; McCormick, A.; Rydzak, C.; Seage, G.R.; Zhang, H.; Hsu, H.E.; Bassett, I.V.; Bender, M.A.; Chung, S.; Ciaranello, A.; Linas, B.P.; Lu, Z.; Morris, B.; Saxena, A.; Sloan, C.; Uhler, L.; Wang, B. 2009: When to start antiretroviral therapy in resource-limited settings Annals of Internal Medicine 151(3): 157-166
Ford, N.; Calmy, A. 2010: Improving first-line antiretroviral therapy in resource-limited settings Current Opinion in HIV and Aids 5(1): 38-47
Berezovskaia, I.V.; Chudinov, M.V. 2005: Ester derivatives of nucleoside inhibitors of reverse transcriptase: II. Molecular systems for combined therapy with 3'-azido-3'-deoxythymidine and 2',3'-didehydro-3'-deoxythymidine Bioorganicheskaia Khimiia 31(5): 451-465
Li, Z.-C.; Li, H.-J.; Dai, L.-L.; Gao, Y.-Q.; Cai, W.-P.; Li, H.-Y.; Huang, X.-J.; Zhang, T.; Wu, H. 2010: Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy Chinese Medical Journal 123(24): 3587-3590
Prendergast, A; Cotton, M; Gibb, D M 2008: When should antiretroviral therapy be started for HIV-infected infants in resource-limited settings? Future HIV Therapy 2(3): 201-208
Hirschhorn, L.R.; Oguda, L.; Fullem, A.; Dreesch, N.; Wilson, P. 2006: Estimating health workforce needs for antiretroviral therapy in resource-limited settings Human Resources for Health 4: 1
Tarby, C.M. 2004: Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors Current Topics in Medicinal Chemistry 4(10): 1045-1057
Wainberg, M.A.; Sawyer, J.P.C.; Montaner, J.S.G.; Murphy, R.L.; Kuritzkes, D.R.; Raffi, F. 2005: Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection Antiviral Therapy 10(1): 13-28
Vitoria, M.; Vella, S.; Ford, N. 2013: Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges Current Opinion in HIV and Aids 8(1): 12-18
Sawe, F.K.; McIntyre, J.A. 2009: Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 49(3): 463-465
Gallant, J.E.; Mehta, S.H.; Sugarman, J. 2013: Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings? Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 57(6): 884-887